not to to get ahead of ourselves but in my mind todays circa 100m market cap should be closer to 200-400m if we didn't have such a habit of over promising on deals and if we had more cash. ie todays price isn't the right starting point for valuation.
I think fda approval and a deal will mean we re rate and I agree paro hopefully funds. deals plural mean I hope we sit around the 2 buck range for a while and even pre revenue as we progress to the end of the trial I don't think It is impossible we are 3-4-5 bucks. to your point PE in year 1-3 isn't so relevant, it's about is the drug getting sales traction and is it potentially a blockbuster.
at this point it's just a dream. I'm focused as I believe PAR is on fda / funding. let's cross that bridge first !
Sharewise Presentation 22/7/24, page-67
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
28.5¢ |
Change
-0.005(1.72%) |
Mkt cap ! $99.69M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 29.0¢ | 28.5¢ | $34.79K | 121.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 70181 | 28.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.0¢ | 10000 | 1 |
View Market Depth
| Last trade - 14.42pm 24/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |